- Q4 2021 net loss was
$(0.48) per basic and diluted share and adjusted non-GAAP net income* was$0.87 per basic and$0.85 per diluted share - FY 2021 net loss was
$(0.66) per basic and diluted share and adjusted non-GAAP net income* was$2.64 per basic and$2.59 per diluted share - Early trends1 indicate that Q1 2022 revenue is expected to be in the range of
$120 million -$130 million and adjusted non-GAAP earnings per share* in the range of$3.80 -$4.10 - Commenced shipment of vasopressin, a generic alternative to Vasostrict®, with 180 days of marketing exclusivity
- Announced commercial availability of novel product, PEMFEXY™ (pemetrexed for injection), a branded alternative to ALIMTA®
- On track to support submission of new drug application in second quarter of 2022 for Landiolol, a beta-1 adrenergic blocker
- Expects to start clinical trial in CAL02 patients in Q3 2022 during pneumonia season
Business and Recent Highlights:
- Announced the commercial availability of its novel product, PEMFEXY™ (pemetrexed for injection), a branded alternative to ALIMTA®. PEMFEXY is a ready-to-use liquid with a unique J-code and is approved in
the United States to treat nonsquamous non-small cell lung cancer and mesothelioma. Eagle received approval from theU.S. Food and Drug Administration (“FDA”) inFebruary 2020 of its new drug application (“NDA”) for PEMFEXY, following the settlement agreement of patent litigation withEli Lilly and Company inDecember 2019 . The agreement provided for a release of all claims by the parties and allows for an initial entry of PEMFEXY into the market (equivalent to approximately a three-week supply of ALIMTA utilization) onFebruary 1, 2022 , and a subsequent uncapped entry onApril 1, 2022 . The ALIMTA U.S. market totaled$1.2 billion for the 12 months endedDecember 31, 2021 , as reported byEli Lilly and Company - Commenced shipment of vasopressin on
January 18, 2022 with 180 days of marketing exclusivity. Vasopressin, an A-rated generic alternative to Vasostrict®, is indicated for use to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.U.S. sales of Vasostrict totaled$901.7 million for the 12 months endedDecember 31, 2021 , as reported by Endo International plc. AOP Orphan Pharmaceuticals GmbH , Member of theAOP Health Group , (“AOP Health”), with whom Eagle entered into a licensing agreement inAugust 2021 , has engaged with the FDA to obtain alignment on the content and format of the pre-clinical and clinical data required to support an NDA seeking approval of Landiolol, a novel therapeutic, for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. Based on the FDA’s responses to AOP Health’s communications, Eagle remains on track to support AOP Health’s NDA filing for Landiolol in the second quarter of 2022.
1 The Company’s expectations with respect to the first quarter of 2022 are based on its estimates and assumptions as of
* Adjusted non-GAAP net income, adjusted non-GAAP earnings per share, adjusted non-GAAP R&D expense and adjusted non-GAAP SG&A expense are non-GAAP financial measures. For descriptions and reconciliations of these non-GAAP financial measures to their most comparable GAAP financial measures, please see below and the tables at the end of this press release.
Financial Highlights
Fourth Quarter 2021
- Total revenue for Q4 2021 was
$42.3 million , compared to$49.9 million in Q4 2020, primarily reflecting lower product sales of BELRAPZO and RYANODEX and lower royalty revenue of BENDEKA, partially offset by higher product sales of TREAKISYM. - Q4 2021 net loss was
$6.2 million , or$(0.48) per basic and diluted share, compared to net income of$8.1 million , or$0.62 per basic and$0.60 per diluted share, in Q4 2020. - Q4 2021 adjusted non-GAAP net income* was
$11.2 million , or$0.87 per basic and$0.85 per diluted share, compared to adjusted non-GAAP net income* of$12.8 million , or$0.98 per basic and$0.96 per diluted share, in Q4 2020. - Cash and cash equivalents were
$97.7 million , net accounts receivable was$41.1 million , and debt was$26.0 million as ofDecember 31, 2021 .
Full Year 2021
- Total revenue for the 12 months ended
December 31, 2021 was$171.5 million , compared to$187.8 million in 2020. 2020 included a$5.0 million milestone payment from SymBio Pharmaceuticals Limited for regulatory approval of TREAKISYM ready-to-dilute (“RTD”) (250 ml) liquid bendamustine formulation.
- Net loss for the 12 months ended
December 31, 2021 was$8.6 million , or$(0.66) per basic and diluted share, compared to net income of$12.0 million , or$0.89 per basic and$0.87 per diluted share, in 2020.
- Adjusted non-GAAP net income* for the 12 months ended
December 31, 2021 was$34.4 million , or$2.64 per basic and$2.59 per diluted share, compared to$48.7 million , or$3.62 per basic and$3.54 per diluted share, in 2020.
- From
August 2016 throughDecember 31, 2021 , Eagle has repurchased$228.1 million of its common stock.
“With two important launches in early 2022, Eagle is off to a great start. The initial impressive revenue generated from vasopressin and PEMFEXY, each with significant periods of exclusivity, together with our royalties from bendamustine sales in
Fourth Quarter 2021 Financial Results
Total revenue for the three months ended
| Three Months Ended |
||||||
| 2021 | 2020 | |||||
| (unaudited) | (unaudited) | |||||
| Revenue (in thousands): | ||||||
| Product sales, net | $ | 16,158 | $ | 22,936 | ||
| Royalty revenue | 26,162 | 26,980 | ||||
| Total revenue | $ | 42,320 | $ | 49,916 | ||
Q4 2021 BELRAPZO product sales were
Q4 2021 RYANODEX® product sales were
Royalty revenue was
Gross margin was 71% during the fourth quarter of 2021, as compared to 75% in the fourth quarter of 2020. The decrease in gross margin for the fourth quarter of 2021 was driven by revenue mix.
R&D expense was
SG&A expenses in the fourth quarter of 2021 totaled
Net loss for the fourth quarter of 2021 was
Adjusted non-GAAP net income* for the fourth quarter of 2021 was
Full Year 2021 Financial Results
Total revenue for the year ended
| Twelve Months Ended |
||||||
| 2021 | 2020 | |||||
| Revenue (in thousands): | ||||||
| Product sales, net | $ | 65,023 | $ | 72,323 | ||
| Royalty revenue | 106,523 | 110,479 | ||||
| License and other revenue | — | 5,000 | ||||
| Total revenue | $ | 171,546 | $ | 187,802 | ||
Product sales decreased by
Gross margin was 75% in 2021, as compared to 76% in 2020. The decrease in gross margin in 2021 was driven by revenue mix.
R&D expense increased to
SG&A expenses decreased by
Net loss for the year ended
Adjusted non-GAAP net income* for the year ended
First Quarter 2022 Expected Revenue and EPS1
- Revenue for the first quarter 2022 is expected to be in the range of
$120 million -$130 million .
- Adjusted non-GAAP earnings per share* for the first quarter 2022 is expected to be in the range of
$3.80 -$4.10 .
2022 Full Year Expense Guidance
- Adjusted non-GAAP R&D expense* is expected to be in the range of
$46 million to$50 million , as compared to$32.5 million in 2021.
- Adjusted non-GAAP SG&A expense* is expected to be in the range of
$54 million to$58 million , as compared to$54.9 million in 2021.
Liquidity
As of
In the fourth quarter of 2021, Eagle purchased
Conference Call
As previously announced, Eagle management will host its fourth quarter 2021 conference call as follows:
| Date | |
| Time | |
| Toll free ( |
866-831-8713 |
| International | 203-518-9822 |
| Webcast (live and replay) | www.eagleus.com, under the “Investor + News” section |
A replay of the conference call will be available for one week after the call's completion by dialing 800-839-0866 (US) or 402-220-0662 (International) and entering conference call ID EGRXQ421. The webcast will be archived for 30 days at the aforementioned URL.
About
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include vasopressin, PEMFEXY™, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM (
Forward-Looking Statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “may,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “near future,” “belief,” “guidance,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events such as: the Company’s financial projections and guidance, including its expected earnings expense for 2022, including expected R&D and SG&A expense, and expected revenue and earnings per share for the first quarter 2021; the Company’s ability to obtain and maintain regulatory approval of its products and product candidates; the Company's clinical development plan for its product candidates, including the number and timing of development initiatives or new indications for the Company’s product candidates; the Company’s timing and ability to enroll patients in upcoming clinical trials; the timing, scope or likelihood and timing of regulatory filings and approvals from the FDA for the Company’s product candidates, including Landiolol and its fulvestrant product; the progress and success of the Company’s launch of any products, including vasopressin and PEMFEXY; the ability of the Company to successfully commercialize its product candidates, including vasopressin and PEMFEXY; the ability of vasopressin to benefit providers and patients as an alternative to Vasostrict; the period of marketing exclusivity for any of the Company’s products or product candidates, including vasopressin; the timing, scope or likelihood and timing of regulatory filings and approvals from the FDA for the Company’s product candidates and the Company’s ability to maintain regulatory approval of its products and product candidates; the Company's clinical development plan for the product candidates in its portfolio; the implementation of certain healthcare reform measures; the ability of the Company to obtain and maintain coverage and adequate reimbursement for its products; the success of the Company's collaborations with its strategic partners and the timing and results of these partners’ preclinical studies and clinical trials, and the Company’s potential earnings potential through such collaborations; the ability of the Company’s executive team to execute on the Company’s strategy and to utilize its cash and other assets to increase shareholder value; and the ability of the Company’s product candidates to deliver value to stockholders; the Company's ability to deliver value in 2022 and over the long term; the Company’s ability to utilize its cash and other assets to increase shareholder value; the Company’s ability to effectively manage and control expenses in line with its budget; and the Company's plans and ability to advance the products in its pipeline; the Company’s ability to complete business development transactions in a timely manner, on favorable terms to the Company, or at all; the sufficiency of the Company’s cash flows and capital resources; the Company’s ability to achieve expected future financial performance and results; the completion of the first quarter of 2022 and the financial closing procedures for the period and other developments that may arise that would cause the Company’s expectations with respect to the Company’s first quarter 2022 revenue expectations to differ, perhaps materially, from the financial results that will be reflected in the Company’s reported financial results for the first quarter of 2022. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company's control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the impacts of the COVID-19 pandemic, including disruption or impact in the sales of the Company's marketed products, interruptions or other adverse effects to clinical trials, delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems, disruption in the operations of the Company's third party partners and disruption of the global economy, and the overall impact of the COVID-19 pandemic on the Company's business, financial condition and results of operations; whether the Company will incur unforeseen expenses or liabilities or other market factors; whether the Company will successfully implement its development plan for its product candidates; delay in or failure to obtain regulatory approval of the Company's or its partners’ product candidates; whether the Company can successfully market and commercialize its product candidates; the success of the Company's relationships with its partners; the availability and pricing of third party sourced products and materials; the outcome of litigation involving any of its products or that may have an impact on any of our products; successful compliance with the FDA and other governmental regulations applicable to product approvals, manufacturing facilities, products and/or businesses; general economic conditions, including the potential adverse effects of public health issues, including the COVID-19 pandemic, on economic activity and the performance of the financial markets generally; the strength and enforceability of the Company's intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and the potential for competition from generic entrants into the market; the risks inherent in the early stages of drug development and in conducting clinical trials; factors in addition to the foregoing that may impact the Company’s financial projects and guidance, including among other things, any potential business development transactions, acquisitions, restructurings or legal settlements, in addition to any unanticipated factors, that may cause the Company’s actual results and outcomes to materially differ from its projections and guidance; and those risks and uncertainties identified in the “Risk Factors” sections of the Company's Quarterly Report on Form 10-Q for the quarter ended
Non-GAAP Financial Performance Measures
In addition to financial information prepared in accordance with
Adjusted non-GAAP net income excludes amortization expense, stock-based compensation expense, depreciation expense, expense of acquired in-process research and development, severance, expense related to collaboration with Tyme, non-cash interest expense, fair value adjustments on equity investment, convertible promissory note related credit losses, fair value adjustments related to derivative instrument, accretion of discount on convertible promissory note and the tax effect of these adjustments.
The Company believes the use of non-GAAP financial measures helps indicate underlying trends in the Company’s business and are important in comparing current results with prior period results and understanding projected operating performance. Non-GAAP financial measures provide the Company and its investors with an indication of the Company’s baseline performance before items that are considered by the Company not to be reflective of the Company’s ongoing results. See the attached reconciliation tables for details of the amounts excluded and included to arrive at certain of the non-GAAP financial measures.
Investors should note that reconciliations of the forward-looking or projected non-GAAP financial measures included in this press release to their most comparable GAAP financial measures cannot be provided because the Company cannot do so without unreasonable efforts due to the unavailability of information needed to calculate the reconciling items and the variability, complexity, and limited visibility of comparable GAAP measures, and the reconciling items that would be excluded from the non-GAAP financial measures in the future. Reconciliations of the components of projected adjusted non-GAAP R&D, SG&A, net income, and earning per share to their most comparable GAAP financial measures is not provided because the quantification of projected GAAP R&D, SG&A, net income and earning per share and the reconciling items between projected GAAP to adjusted non-GAAP R&D, SG&A, net income, and earnings per share cannot be reasonably calculated or predicted at this time without unreasonable efforts. For example, with respect to GAAP net income, the Company is not able to calculate the favorable or unfavorable expenses related to the fair value adjustments on equity investments and derivative instruments primarily due to nature of these transactions. Such unavailable information could be significant such that actual GAAP R&D, SG&A, net income, and earnings per share would vary significantly from projected GAAP and adjustment non-GAAP R&D, SG&A, net income, and earnings per share.
These non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information prepared in accordance with
Investor Relations for
T: 212-452-2793
E: lwilson@insitecony.com
-- Financial tables follow –
| CONSOLIDATED BALANCE SHEETS | ||||||||
| (In thousands, except share amounts) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 97,659 | $ | 103,155 | ||||
| Accounts receivable, net | 41,149 | 51,117 | ||||||
| Inventories | 21,908 | 8,075 | ||||||
| Prepaid expenses and other current assets | 11,890 | 3,718 | ||||||
| Total current assets | 172,606 | 166,065 | ||||||
| Property and equipment, net | 1,636 | 2,077 | ||||||
| Intangible assets, net | 10,671 | 12,917 | ||||||
| 39,743 | 39,743 | |||||||
| Deferred tax asset, net | 18,798 | 15,180 | ||||||
| Other assets | 10,278 | 17,208 | ||||||
| Total assets | $ | 253,732 | $ | 253,190 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 16,431 | $ | 6,268 | ||||
| Accrued expenses and other liabilities | 32,338 | 23,817 | ||||||
| Short-term debt | 25,607 | 8,000 | ||||||
| Total current liabilities | 74,376 | 38,085 | ||||||
| Other long-term liabilities | 2,903 | 3,959 | ||||||
| Long-term debt | — | 25,135 | ||||||
| Total liabilities | 77,279 | 67,179 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding as |
— | — | ||||||
| Common stock, |
17 | 17 | ||||||
| Additional paid in capital | 325,779 | 305,403 | ||||||
| Accumulated other comprehensive loss | (94 | ) | — | |||||
| Retained earnings | 75,862 | 84,489 | ||||||
| (225,111 | ) | (203,898 | ) | |||||
| Total stockholders' equity | 176,453 | 186,011 | ||||||
| Total liabilities and stockholders' equity | $ | 253,732 | $ | 253,190 | ||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended |
Year Ended |
|||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| Revenue: | ||||||||||||||||
| Product sales, net | $ | 16,158 | $ | 22,936 | $ | 65,023 | $ | 72,323 | ||||||||
| Royalty revenue | 26,162 | 26,980 | 106,523 | 110,479 | ||||||||||||
| License and other revenue | — | — | — | 5,000 | ||||||||||||
| Total revenue | 42,320 | 49,916 | 171,546 | 187,802 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of product sales | 9,693 | 9,843 | 31,528 | 33,647 | ||||||||||||
| Cost of royalty revenue | 2,616 | 2,698 | 10,652 | 11,818 | ||||||||||||
| Research and development | 3,787 | 9,395 | 51,275 | 30,785 | ||||||||||||
| Selling, general and administrative | 20,325 | 18,187 | 75,322 | 78,598 | ||||||||||||
| Total operating expenses | 36,421 | 40,123 | 168,777 | 154,848 | ||||||||||||
| Income from operations | 5,899 | 9,793 | 2,769 | 32,954 | ||||||||||||
| Interest income | 165 | 20 | 560 | 562 | ||||||||||||
| Interest expense | (395 | ) | (413 | ) | (1,635 | ) | (2,577 | ) | ||||||||
| Other (expense) income | (4,445 | ) | 1,987 | (6,242 | ) | (8,262 | ) | |||||||||
| Total other (expense) income, net | (4,675 | ) | 1,594 | (7,317 | ) | (10,277 | ) | |||||||||
| Income (loss) before income tax provision | 1,224 | 11,387 | (4,548 | ) | 22,677 | |||||||||||
| Income tax provision | (7,420 | ) | (3,330 | ) | (4,079 | ) | (10,688 | ) | ||||||||
| Net (loss) income | $ | (6,196 | ) | $ | 8,057 | $ | (8,627 | ) | $ | 11,989 | ||||||
| (Loss) earnings per common share: | ||||||||||||||||
| Basic | $ | (0.48 | ) | $ | 0.62 | $ | (0.66 | ) | $ | 0.89 | ||||||
| Diluted | $ | (0.48 | ) | $ | 0.60 | $ | (0.66 | ) | $ | 0.87 | ||||||
| Weighted average number of common shares outstanding: | ||||||||||||||||
| Basic | 12,896,471 | 13,066,189 | 13,051,095 | 13,481,525 | ||||||||||||
| Diluted | 12,896,471 | 13,331,149 | 13,051,095 | 13,771,393 | ||||||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| (In thousands) | ||||||||
| Year Ended |
||||||||
| 2021 | 2020 | |||||||
| Cash flows from operating activities: | ||||||||
| Net (loss) income | $ | (8,627 | ) | $ | 11,989 | |||
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | ||||||||
| Deferred income taxes | (3,618 | ) | (1,511 | ) | ||||
| Depreciation expense | 764 | 872 | ||||||
| Noncash operating lease expense related to right-of-use assets | 1,046 | 1,228 | ||||||
| Amortization expense of intangible assets | 2,996 | 2,666 | ||||||
| Convertible promissory note related credit losses | 758 | — | ||||||
| Stock-based compensation expense | 19,555 | 24,756 | ||||||
| Fair value adjustments on equity investment | 6,170 | 5,300 | ||||||
| Amortization of debt issuance costs | 472 | 419 | ||||||
| Fair value adjustments on settled accelerated share repurchase agreement | — | 2,962 | ||||||
| Fair value adjustments related to derivative instrument | (686 | ) | — | |||||
| Accretion of discount on convertible promissory note | (148 | ) | — | |||||
| Changes in operating assets and liabilities which provided (used) cash: | ||||||||
| Accounts receivable | 9,529 | (3,113 | ) | |||||
| Inventories | (13,833 | ) | (1,509 | ) | ||||
| Prepaid expenses and other current assets | (2,770 | ) | 11,386 | |||||
| Other assets | (1,321 | ) | (2,325 | ) | ||||
| Accounts payable | 10,162 | 806 | ||||||
| Accrued expenses and other liabilities | 7,770 | (4,429 | ) | |||||
| Net cash provided by operating activities | 28,219 | 49,497 | ||||||
| Cash flows from investing activities: | ||||||||
| Purchase of equity investment security | — | (17,500 | ) | |||||
| Purchase of property and equipment | (323 | ) | (747 | ) | ||||
| Purchase of convertible promissory note | (5,000 | ) | — | |||||
| Net cash used in investing activities | (5,323 | ) | (18,247 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Repurchases of common stock | (21,213 | ) | (34,999 | ) | ||||
| Proceeds from existing revolving credit facility | — | 110,000 | ||||||
| Repayment of existing revolving credit facility | — | (110,000 | ) | |||||
| Payment of debt | (8,000 | ) | (5,000 | ) | ||||
| Payment of employee withholding tax upon vesting of stock-based awards | (1,577 | ) | (1,525 | ) | ||||
| Proceeds from common stock option exercises | 2,398 | 3,654 | ||||||
| Net cash used in financing activities | (28,392 | ) | (37,870 | ) | ||||
| Net decrease in cash and cash equivalents | (5,496 | ) | (6,620 | ) | ||||
| Cash and cash equivalents at beginning of period | 103,155 | 109,775 | ||||||
| Cash and cash equivalents at end of period | $ | 97,659 | $ | 103,155 | ||||
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid during the period for: | ||||||||
| Income taxes, net | $ | 10,005 | $ | 6,428 | ||||
| Interest | 1,197 | 2,224 | ||||||
| Right-of-use asset obtained in exchange for lease obligation, inclusive of a lease amendment | 270 | 855 | ||||||
| RECONCILIATION OF GAAP TO ADJUSTED NON-GAAP NET INCOME AND | ||||||||||||||||
| ADJUSTED NON-GAAP EARNINGS PER SHARE (UNAUDITED) | ||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended |
Twelve Months Ended |
|||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Net (loss) income - GAAP | $ | (6,196 | ) | $ | 8,057 | $ | (8,627 | ) | $ | 11,989 | ||||||
| Adjustments: | ||||||||||||||||
| Cost of product revenues: | ||||||||||||||||
| Amortization expense | 675 | 262 | 1,578 | 1,046 | ||||||||||||
| Research and development: | ||||||||||||||||
| Stock-based compensation expense | 505 | 612 | 2,682 | 2,682 | ||||||||||||
| Depreciation expense | 56 | 63 | 220 | 269 | ||||||||||||
| Expense of acquired in-process research & development | 339 | - | 15,339 | - | ||||||||||||
| Severance | 260 | - | 534 | - | ||||||||||||
| Selling, general and administrative: | ||||||||||||||||
| Stock-based compensation expense | 4,177 | 5,709 | 16,873 | 22,074 | ||||||||||||
| Expense related to collaboration with Tyme | - | - | - | 2,500 | ||||||||||||
| Amortization expense | 203 | 405 | 1,418 | 1,620 | ||||||||||||
| Depreciation expense | 133 | 153 | 544 | 603 | ||||||||||||
| Severance | 1,216 | 679 | 1,550 | 924 | ||||||||||||
| Other: | ||||||||||||||||
| Non-cash interest expense | 118 | 118 | 472 | 472 | ||||||||||||
| Fair value adjustments on equity investment | 4,270 | (2,400 | ) | 6,170 | 5,300 | |||||||||||
| Convertible promissory note related credit losses | 608 | - | 758 | - | ||||||||||||
| Fair value adjustments related to derivative instrument | (432 | ) | 413 | (686 | ) | 2,962 | ||||||||||
| Accretion of discount on convertible promissory note | (46 | ) | - | (148 | ) | - | ||||||||||
| Tax effect of the non-GAAP adjustments | 5,332 | (1,233 | ) | (4,276 | ) | (3,699 | ) | |||||||||
| Adjusted non-GAAP net income | $ | 11,218 | $ | 12,838 | $ | 34,401 | $ | 48,742 | ||||||||
| Adjusted non-GAAP earnings per share: | ||||||||||||||||
| Basic | $ | 0.87 | $ | 0.98 | $ | 2.64 | $ | 3.62 | ||||||||
| Diluted | $ | 0.85 | $ | 0.96 | $ | 2.59 | $ | 3.54 | ||||||||
| Weighted average number of common shares outstanding: | ||||||||||||||||
| Basic | 12,896,471 | 13,066,189 | 13,051,095 | 13,481,525 | ||||||||||||
| Diluted | 13,203,666 | 13,331,149 | 13,265,181 | 13,771,393 | ||||||||||||
| RECONCILIATION OF GAAP TO ADJUSTED NON-GAAP EBITDA (UNAUDITED) | |||||||||||||||
| (In thousands) | |||||||||||||||
| Three Months Ended |
Twelve Months Ended |
||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||
| Net (loss) income - GAAP | $ | (6,196 | ) | $ | 8,057 | $ | (8,627 | ) | $ | 11,989 | |||||
| Add back: | |||||||||||||||
| Interest expense, net of interest income | 230 | 393 | 1,075 | 2,015 | |||||||||||
| Income tax provision | 7,420 | 3,330 | 4,079 | 10,688 | |||||||||||
| Depreciation and amortization expense | 1,067 | 883 | 3,760 | 3,538 | |||||||||||
| Add back: | |||||||||||||||
| Stock-based compensation expense | 4,682 | 6,321 | 19,555 | 24,756 | |||||||||||
| Fair value adjustments on equity investment | 4,270 | (2,400 | ) | 6,170 | 5,300 | ||||||||||
| Expense of acquired in-process research & development | 339 | - | 15,339 | - | |||||||||||
| Convertible promissory note related credit losses | 608 | - | 758 | - | |||||||||||
| Fair value adjustments related to derivative instrument | (432 | ) | 413 | (686 | ) | 2,962 | |||||||||
| Expense related to collaboration with Tyme | - | - | - | 2,500 | |||||||||||
| Severance | 1,476 | 679 | 2,084 | 924 | |||||||||||
| Adjusted Non-GAAP EBITDA | $ | 13,464 | $ | 17,676 | $ | 43,507 | $ | 64,672 | |||||||
Source: Eagle Pharmaceuticals, Inc.